The clinical value of plasma NT-proBNP detection in evaluation of major adverse cardiac event in chronic heart failure patients during hospitalization
10.3760/cma.j.issn.1008-6706.2013.20.004
- VernacularTitle:血浆氨基末端B型利钠肽原检测在慢性心力衰竭患者住院期间主要心血管不良事件评估中的价值
- Author:
Chunde ZHANG
;
Jiawei LIU
;
Bin CHEN
;
Aiping ZHANG
- Publication Type:Journal Article
- Keywords:
Heart failure,congestive;
Heart function tests;
Natriuretic peptide,brain
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(20):3050-3052
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of plasma NT-proBNP in evaluation of major adverse cardiac event in chronic heart failure patients.Methods 120 chronic heart failure patients who measured plasma NT-proBNP were divided into two groups according to median plasma NT-proBNP level (A group:≤ median,B group:＞ median).The incidence of major adverse cardiac events,MACE(including malignant ventricular arrhythmia and sudden cardiac death) were observed during hospitalization.Results The left ventricular end-diastolic diameters (LVEDDs) in B group was longer than that in A group [(58.80 ± 6.90) mm vs (54.32 ± 8.00) mm,P =0.035)],and the left ventricular ejection fraction(LYEF) in B group was lower than that in A group[(29.16 ± 8.31) ％ vs (33.80 ± 6.90)％,P =0.037].The incidence rate of major adverse cardiac events in A group was higher than that in B group (11.63％ vs 1.67 ％,P ＜ 0.05).The multivariate Logistic regression analysis showed that the NT-proBNP level in chronic heart failure inpatients was independently associated with major adverse cardiac event during hospitalization(OR =5.28,95％ confidence intervals 3.54 ～9.26,P＜0.05).Conclusion In chronic heart failure patients,plasma NT-proBNP level could predict the MACE incidence during hospitalization,and have important value to evaluate the prognosis of chronic heart failure.
